CALL NOW 1-800-229-7989 or CHAT LIVE for a free consultation.


Home / Dangerous Drugs / Onglyza


A United States Food and Drug Administration (FDA) advisory committee has raised red flags regarding two dipeptidyl peptidase-4 inhibitors: Onglyza (saxagliptin, Bristol-Myers Squibb/AstraZeneca) and Nesina (algoliptin, Takeda Pharmaceuticals).

The FDA panelists noted that patients taking this class of diabetes medication had a 27 percent increase in the rate of hospitalization for heart failure. They further established that there was a potential for an increased risk of death overall, regardless of cause.

Other elevated risks included:

  • Heart Failure
  • Congestive Heart Failure
  • Cardiac Failure
  • Death from Heart Failure
  • Pancreatic Cancer

If you or someone you love has had complications related to Onglyza, call Alexander Shunnarah Personal Injury Attorneys today at 1-800-229-7989.

Patients with diabetes may feel as though they are faced with a gauntlet of choices: take a medication and risk complications or refrain from medicating and risk uncontrolled blood sugar levels. At Alexander Shunnarah Personal Injury Attorneys, we understand how frustrating it can be to feel like a victim and we’re dedicated to empowering patients and their families by helping them make an informed decision on whether filing an Onglyza lawsuit is right for them.

To learn more about our National Onglyza Representation visit here.

For more information visit